Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2006 > Volume 15 Number 1 January 2006 > DEVICE EVALUATION > Twenty-Year Results of the Hancock II Bioprosthesis

Twenty-Year Results of the Hancock II Bioprosthesis

Michael A. Borger, Joan Ivanov, Susan Armstrong, Debbie Christie-Hrybinsky, Christopher M. Feindel, Tirone E. David 

Division of Cardiovascular Surgery, Toronto General Hospital, University Health Network, and Department of Surgery, University of Toronto, Toronto, Ontario, Canada

Background and aim of the study: The Hancock II bioprosthesis (HII) has several design features designed to increase its durability. The study aim was to determine very long-term outcomes for the HII valve in a large patient population.
Methods: Long-term follow up was obtained by mail and/or telephone questionnaire of patients undergoing HII valve replacement surgery between 1982 and 2001 (n = 1,569). Follow up was complete on 1,568 patients (99.9%), and ranged from 0 to 250 months.
Results: Isolated aortic valve replacement (AVR) was performed in 1,010 patients and mitral valve replacement (MVR) in 559. The average (±SD) age of patients was 67 ± 11 years, and 65% were males. Long-term death occurred in 445 AVR patients and 275 MVR patients, of which 11% and 17%, respectively, were valve-related. Twenty-year freedom from thromboembolism (all results actuarial) was 79

± 3% after AVR and 83 ± 3% after MVR; freedom from endocarditis was 91 ± 5% and 85 ± 5%, respectively. Twenty-year freedom from structural valve deterioration (SVD) was 73 ± 16% and 39 ± 9% in AVR patients aged ≥65 years and <65 years, respectively. Similarly, 20-year freedom from SVD was 59 ± 11% and 27 ± 9% in MVR patients aged ≥65 years and <65 years, respectively. When actual statistical techniques were applied (cumulative incidence), 20-year actual risk of SVD was 18 ± 3% in all AVR patients and 23 ± 3% in all MVR patients. Reoperation was required in 72 AVR patients, and was valve-related in 60. A total of 49 MVR patients underwent reoperation; 48 of these were valve-related.
Conclusion: The Hancock II bioprosthesis continues to show very good long-term results and durability, particularly in patients aged over 65 years.
The Journal of Heart Valve Disease 2006;15:49-56

Twenty-Year Results of the Hancock II Bioprosthesis

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.